ABIO ARCA biopharma Inc.

0.52
+0.02  (+4%)
Previous Close 0.5
Open 0.52
Price To Book 0.96
Market Cap 7240510
Shares 13,924,058
Volume 47,666
Short Ratio
Av. Daily Volume 568,572

NewsSee all news

  1. ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update
  2. GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions
  3. ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions
  4. Westminster biotech company receives second extension on delisting notice from Nasdaq
  5. Today's Research Reports on Trending Tickers: ARCA biopharma and Nektar Therapeutics

SEC filingsSee all SEC filings

  1. 8-K - Current report 181184607
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181183697
  3. 8-K - Current report 181128484
  4. 8-K - Current report 181113827
  5. DEF 14A - Other definitive proxy statements 181079503

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released February 26, 2018 - no benefit shown in overall population. Received "no agreement" letter from FDA regarding SPA. Intends to meet FDA December 2018 regarding letter.
Gencaro - GENETIC-AF trial
Chronic Heart Failure

Latest News

  1. ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update
  2. GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions
  3. ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions
  4. Westminster biotech company receives second extension on delisting notice from Nasdaq
  5. Today's Research Reports on Trending Tickers: ARCA biopharma and Nektar Therapeutics
  6. ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
  7. Marijuana Stocks: Biotech Stock Report: 3 Companies To Watch In August 2018
  8. 3 Biotech Stocks in Focus on Tuesday
  9. Today’s Research Reports on Stocks to Watch: Progenics Pharmaceuticals and Arca Biopharma
  10. Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks
  11. Today’s Research Reports on Stocks to Watch: vTv Therapeutics and ARCA Biopharma
  12. Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks
  13. Blog Exposure - Insmed Announced Submission of New Drug to FDA for Patients with Nontuberculous Mycobacterial Lung Disease

SEC Filings

  1. 8-K - Current report 181184607
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181183697
  3. 8-K - Current report 181128484
  4. 8-K - Current report 181113827
  5. DEF 14A - Other definitive proxy statements 181079503
  6. 8-K - Current report 181075798
  7. PRE 14A - Other preliminary proxy statements 181063410
  8. 8-K - Current report 181005498
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 181005264
  10. 8-K - Current report 18981290